Arcturus Therapeutics Holdings Inc. (ARCT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 15.10 |
| Open | 14.92 |
| Bid | 14.83 x 1200 |
| Ask | 16.66 x 800 |
| Day's Range | 14.71 - 15.94 |
| 52 Week Range | 11.70 - 31.41 |
| Volume | |
| Avg. Volume | 336,750 |
| Market Cap | 416.921M |
| Beta (5Y Monthly) | 2.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.29 |
| Earnings Date | Mar 28, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.83 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ARCT
Related Research
- Arcturus Therapeutics HoldingsDaily – Vickers Top Buyers & Sellers for 11/29/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat4 months agoArgus Research
- Zacks
Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock?
Immuneering Corporation (IMRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- Business Wire
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023
SAN DIEGO, March 07, 2023--Arcturus Therapeutics Holdings Inc. (the "Company," "Arcturus," Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2022 after the market close on Tuesday, March 28 and will also host a conference call and webcast
- Business Wire
Arcturus Therapeutics to Attend Upcoming Investor Conferences
SAN DIEGO, February 06, 2023--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences:
